Company

IKTOS (Synsight)

Pépinière Genopole Entreprises, 4 rue Pierre Fontaine
91058 EVRY – FRANCE
Phone: +33 1 69 47 01 76
Email: info@synsight.net

Cyril BAUVAIS: CEO

Web site >

#Therapeutics

Drug discovery
Chemoinformatics
Molecular modeling
High-content screening (HCS)
Artificial intelligence

Program:

Field of Activity

IKTOS (Synsight) is a company specializing in the discovery and preclinical development of new therapeutic molecules, based on a proprietary, integrated platform, combining artificial intelligence, molecular modeling and a functional experimental screening approach of High-Content Screening (HCS ).

BACKGROUND
December 2013: Launch of SYNSIGHT
January 2018: Transition to a platform model for drug discovery
January 2019: Platform prototype ready to sell
July 2024: Acquisition by Iktos

DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
IKTOS (Synsight) platform encompasses artificial intelligence, molecular modeling and high-content screening to rationalize and accelerate the drug discovery projects of its partners.

CUSTOMER REFERENCES / COLLABORATIONS / HIGHLIGHTS

Collaboration with SABNP laboratory (Évry university and INSERM)
Successful consulting activity since 2013

COLLABORATIONS SOUGHT

IKTOS (Synsight) business model involves developing R&D collaborations and licensing agreements with biotech and pharmaceutical companies.

IKTOS (Synsight) takes charge of the discovery of new innovative drug candidates for novel therapeutic targets proposed by the partner.

Further Information

6 staff members
Annual Turnover: €100,000
1 PATENT
Strengths
Collectively, the IKTOS (Synsight) team has over 20 years of experience in chemoinformatics, molecular modeling, computational chemistry, structural biology, protein design and other related fields.
Innovation Assets
The IKTOS (Synsight) platform offers the predictive capacity of artificial intelligence combined with the descriptive and explanatory capacity of molecular modeling furthermore enriched by quantitative and functional experimental data.

Genopole’s Companies

#Therapeutics

In same field

Synaptys neuroscience

SYNAPTYS neuroscience is developing SYS-0108, the first Neuro-Synergistic Conjugate for Alzheimer’s disease—a disruptive, patented innovation inspired by combination strategies used in oncology.

Discover

MicroXpace

Biotechnology for sustainable health solutions in animal farming (aquaculture, poultry, and pet animals) and combating parasitic diseases.

Discover

AGS Therapeutics

AGS Therapeutics is a biotech company pioneering the use of microalgae extracellular vesicles (MEVs) as a universal delivery system for innovative therapeutics, vaccines and gene therapies.

Discover

PHARMING

Pharming specializes in the production of recombinant proteins in transgenic rabbit milk.

Discover

Genosafe

GenoSafe is a full contract research and consulting organization specialized in evaluating the quality, safety and efficacy of innovative biological products. Our goal is to enable our clients to move their products along clinical development rapidly and efficiently.

Discover